

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai MicroPort MedBot (Group) Co., Ltd.

上海微创医疗机器人(集团)股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2252)

**INSIDE INFORMATION ANNOUNCEMENT
LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE FOR
THE H SHARE FULL CIRCULATION OF THE COMPANY**

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”) and Part XIVA (the “**Inside Information Provisions**”) of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 4 February 2026 (the “**Announcement**”) in relation to the notification letter from the China Securities Regulatory Commission regarding the application by the Company for the proposed implementation of H share full circulation. Unless otherwise stated, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE

The board of directors of the Company announces that the Company has received the approval dated 13 February 2026 granted by the Stock Exchange for the listing of and permission to deal in 5,989,798 H shares (the “**Converted H Shares**”), being the total number of unlisted shares to be converted and listed.

SHAREHOLDING STRUCTURE

The conversion and listing will involve an aggregate of 5,989,798 unlisted shares held by two shareholders of the Company (the “**Participating Shareholders**”), representing approximately 0.5808% of the total issued shares of the Company as at the date of this announcement.

Immediately following the completion of the conversion and listing, the number of shares and the shareholding percentage of the Participating Shareholders in the Converted H Shares of the Company are set out as follows:

Name of Participating Shareholders	Number of unlisted shares to be converted into H shares (Shares)	Approximate percentage of the total issued share capital of the Company as at the date of this announcement (%)
Shanghai Runkun Tianlu Enterprise Management Center (LLP) (上海潤昆天祿企業管理中心(有限合夥))	589,806	0.0572%
Shenzhen Xinlong Investment LLP (深圳芯龍投資合夥企業 (有限合夥))	5,399,992	0.5236%
Total	5,989,798	0.5808%

Immediately before and after the completion of the conversion and listing, the shareholding structure of the Company is set out below:

Class of shares	Immediately before completion of the conversion and listing		Immediately after completion of the conversion and listing	
	Number of shares (Shares)	Approximate percentage of the Company's total issued shares (%)	Number of shares (Shares)	Approximate percentage of the Company's total issued shares (%)
Unlisted shares	6,599,543	0.6399%	609,745	0.0591%
H shares	<u>1,024,730,788</u>	<u>99.3601%</u>	<u>1,030,720,586</u>	<u>99.9409%</u>
Total	<u>1,031,330,331</u>	<u>100.00%</u>	<u>1,031,330,331</u>	<u>100.0000%</u>

The Company will complete the relevant procedures in relation to the Converted H Shares. The Company will make further announcement(s) on the progress of the H share full circulation and the conversion and listing in accordance with the Inside Information Provisions and/or the requirements of the Listing Rules.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Dr. Zhaohua Chang
Chairman

Shanghai, China, 13 February 2026

As at the date of this announcement, the executive directors are Dr. Chao He and Mr. Yu Liu, the non-executive directors are Dr. Zhaohua Chang, Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida, Mr. Chen Chen and Ms. Min Liang, and the independent non-executive directors are Dr. Guoen Liu, Mr. Jonathan H. Chou, Mr. Haisong Yao and Mr. Wai Man Chung.